The global ulcerative colitis drug market is expected to reach USD 10.59 billion by 2028, at a CAGR of 5.03% from 2021 to 2028. The increasing prevalence of ulcerative colitis across the globe is expected to be the primary factor driving the growth of the global ulcerative colitis drug market.
Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes long-lasting swelling and inflammation in the lining of the large intestine and rectum. Major symptoms of ulcerative colitis include abdominal pain, diarrhea, rectal bleeding, weight loss, and fatigue.
Market Dynamics
The growth of the global ulcerative colitis drug market is majorly driven by the increasing prevalence of ulcerative colitis across the globe. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), around 1 million people in the United States are affected by ulcerative colitis. The rising awareness about the availability of treatment options for ulcerative colitis is expected to propel the growth of the global ulcerative colitis drug market during the forecast period. Furthermore, various initiatives taken by the government and non-government organizations to raise awareness about the disease and its treatments are likely to drive market growth. On the other hand, the high cost of treatment and stringent regulatory policies are expected to restrain the market growth during the assessment period.
Market Segmentation
The global ulcerative colitis drug market has been segmented based on drug class, distribution channel, and region.
Based on drug class, the global ulcerative colitis drug market has been divided into anti-inflammatory drugs, immunomodulatory, and biologics. The anti-inflammatory drugs segment has been further sub-segmented into aminosalicylates, corticosteroids, and others. The biologics segment has been sub-segmented into infliximab, adalimumab, vedolizumab, and others. The immunomodulators segment has been sub-segmented into azathioprine, mercaptopurine, and others.
Based on the distribution channel, the global ulcerative colitis drug market has been classified into hospitals & pharmacies, and online stores.
Regional Analysis
The global ulcerative colitis drug market has been studied for five major regions—North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America is estimated to dominate the global ulcerative colitis drug market during the forecast period, due to the availability of advanced healthcare infrastructure, high healthcare expenditure, and increasing prevalence of the disease in the region. According to the Crohn’s & Colitis Foundation of America, around 1.6 million people in the United States are affected by IBD, of which 700,000 are affected by ulcerative colitis.
Europe is expected to account for the second-largest share of the global ulcerative colitis drug market. The market growth in the region is attributed to the increasing prevalence of the disease in the region and the rising number of clinical trials conducted for the development of new drugs.
The ulcerative colitis drug market in the Asia-Pacific region is expected to grow at a rapid pace during the forecast period, owing to the increasing healthcare expenditure, rising awareness about the availability of treatment options for ulcerative colitis, and the presence of a large pool of population in the region.
The markets in Latin America and the Middle East & Africa are expected to witness steady growth during the forecast period, due to the increasing prevalence of the disease in the regions.
Key Players
Prominent players operating in the global ulcerative colitis drug market include AbbVie Inc., Janssen Global Services, LLC, Pfizer Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Allergan, Dr. Falk Pharma GmbH, Cosmo Pharmaceuticals, Otsuka Holdings Co., Ltd., and UCB S.A.
Get a comprehensive report summary that describes the market value and forecast along with the research methodology. Download the PDF brochure
